1.Shichita, T., et al., Post-ischemic inflammation in the brain. Front Immunol, 2012. 3: p. 132.
2.Denes, A., et al., Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun, 2010. 24(5): p. 708–23.
3.Tuttolomondo, A., et al., Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des, 2008. 14(33): p. 3574–89.
4.Stoll, G., S. Jander, and M. Schroeter, Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol, 1998. 56(2): p. 149–71.
5.Dong, Y. and E. N. Benveniste, Immune function of astrocytes. Glia, 2001. 36(2): p. 180–90.
6.Ladeby, R., et al., Microglial cell population dynamics in the injured adult central nervous system. Brain Res Brain Res Rev, 2005. 48(2): p. 196–206.
7.Sofroniew, M. V. and H. V. Vinters, Astrocytes: biology and pathology. Acta Neuropathol, 2010. 119(1): p. 7–35.
8.Iglesias, J., L. Morales, and G. E. Barreto, Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs. Mol Neurobiol, 2017. 54(4): p. 2518–2538.
9.Jha, M. K., et al., The secretome signature of reactive glial cells and its pathological implications. Biochim Biophys Acta, 2013. 1834(11): p. 2418–28.
10.Rhee, H. W., et al., Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science, 2013. 339(6125): p. 1328–1331.
11.Allen, I. C., et al., NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity, 2011. 34(6): p. 854–65.
12.Moore, C. B., et al., NLRX1 is a regulator of mitochondrial antiviral immunity. Nature, 2008. 451(7178): p. 573–7.
13.Ma, D., et al., NLRX1 alleviates lipopolysaccharide-induced apoptosis and inflammation in chondrocytes by suppressing the activation of NF-kappaB signaling. Int Immunopharmacol, 2019. 71: p. 7–13.
14.Tattoli, I., et al., NLRX1 Acts as an Epithelial-Intrinsic Tumor Suppressor through the Modulation of TNF-Mediated Proliferation. Cell Rep, 2016. 14(11): p. 2576–86.
15.Gharagozloo, M., et al., NLR-Dependent Regulation of Inflammation in Multiple Sclerosis. Front Immunol, 2017. 8: p. 2012.
16.Theus, M. H., et al., Loss of NLRX1 Exacerbates Neural Tissue Damage and NF-kappaB Signaling following Brain Injury. J Immunol, 2017. 199(10): p. 3547–3558.
17.Xia, X., et al., NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity, 2011. 34(6): p. 843–53.
18.Bonifati, V., et al., Mutations in the DJ–1 gene associated with autosomal recessive early-onset parkinsonism. Science, 2003. 299(5604): p. 256–9.
19.Bandopadhyay, R., et al., The expression of DJ–1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain, 2004. 127(Pt 2): p. 420–30.
20.Peng, L., et al., Effect of DJ–1 on the neuroprotection of astrocytes subjected to cerebral ischemia/reperfusion injury. J Mol Med (Berl), 2019. 97(2): p. 189–199.
21.Waak, J., et al., Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ–1. FASEB J, 2009. 23(8): p. 2478–89.
22.Kim, H. S., et al., DJ–1 controls bone homeostasis through the regulation of osteoclast differentiation. Nat Commun, 2017. 8(1): p. 1519.
23.Kim, J. H., et al., DJ–1 facilitates the interaction between STAT1 and its phosphatase, SHP–1, in brain microglia and astrocytes: A novel anti-inflammatory function of DJ–1. Neurobiol Dis, 2013. 60: p. 1–10.
24.Chen, X., et al., GSK–3beta downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. Sci Rep, 2016. 6: p. 20196.
25.Walsh, M. C., et al., TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL–1 and RANKL. PLoS One, 2008. 3(12): p. e4064.
26.Massa, P. T. and C. Wu, Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP–1. J Interferon Cytokine Res, 1998. 18(7): p. 499–507.
27.Clements, C. M., et al., DJ–1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A, 2006. 103(41): p. 15091–6.
28.Yokota, T., et al., Down regulation of DJ–1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun, 2003. 312(4): p. 1342–8.
29.Fan, J., et al., DJ–1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem, 2008. 283(7): p. 4022–30.
30.Deng, Y., et al., Astrocyte-derived proinflammatory cytokines induce hypomyelination in the periventricular white matter in the hypoxic neonatal brain. PLoS One, 2014. 9(1): p. e87420.
31.Huang, J., U. M. Upadhyay, and R. J. Tamargo, Inflammation in stroke and focal cerebral ischemia. Surg Neurol, 2006. 66(3): p. 232–45.
32.Venters, H. D., R. Dantzer, and K. W. Kelley, Tumor necrosis factor-alpha induces neuronal death by silencing survival signals generated by the type I insulin-like growth factor receptor. Ann N Y Acad Sci, 2000. 917: p. 210–20.
33.Yu, Y., et al., Deficiency of DJ–1 Ameliorates Liver Fibrosis through Inhibition of Hepatic ROS Production and Inflammation. Int J Biol Sci, 2016. 12(10): p. 1225–1235.
34.Kosmider, B., et al., Impaired non-homologous end joining in human primary alveolar type II cells in emphysema. Sci Rep, 2019. 9(1): p. 920.
35.Eitas, T. K., et al., The nucleotide-binding leucine-rich repeat (NLR) family member NLRX1 mediates protection against experimental autoimmune encephalomyelitis and represses macrophage/microglia-induced inflammation. J Biol Chem, 2014. 289(7): p. 4173–9.
36.Neel, B. G., Structure and function of SH2-domain containing tyrosine phosphatases. Semin Cell Biol, 1993. 4(6): p. 419–32.
37.Kanwal, Z., et al., Deficiency in hematopoietic phosphatase ptpn6/Shp1 hyperactivates the innate immune system and impairs control of bacterial infections in zebrafish embryos. J Immunol, 2013. 190(4): p. 1631–45.
38.Zhang, Z., E. Jimi, and A. L. Bothwell, Receptor activator of NF-kappa B ligand stimulates recruitment of SHP–1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J Immunol, 2003. 171(7): p. 3620–6.
39.Xie, P., TRAF molecules in cell signaling and in human diseases. J Mol Signal, 2013. 8(1): p. 7.
40.Chen, X. Q., et al., Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-kappaB/TGF-beta1/TRIF/TRAF6 pathway. Exp Cell Res, 2015. 330(1): p. 43–55.
41.Lamothe, B., et al., The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin–1, lipopolysaccharide, and RANKL. J Biol Chem, 2008. 283(36): p. 24871–80.
42.Walsh, M. C., J. Lee, and Y. Choi, Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system. Immunol Rev, 2015. 266(1): p. 72–92.